The US Food and Drug Administration (FDA) has cleared Molecular Designs’ SimplicityDx FluA/FluB/RSV panel, marking the company’s first cleared diagnostic assay.

The multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) test identifies and differentiates influenza A, influenza B, and respiratory syncytial virus (RSV) RNA from anterior nasal swabs taken from individuals displaying symptoms of respiratory tract infection.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Influenza and RSV often circulate simultaneously, placing pressure on testing facilities during peak respiratory periods. Analysing all three viruses in a single run helps laboratories maintain workflow during high-demand months. Results are intended to aid differential diagnosis alongside other clinical, epidemiological, and laboratory findings.

Molecular Designs CEO, Michael Clark, said: “This is a defining moment for Molecular Designs. Earning FDA clearance requires rigorous manufacturing, robust quality systems and scientific discipline, and our team built all three. With respiratory season underway, we’re ready to support labs with a cleared, practical way to test for flu A, flu B and RSV in a single run.”

The assay includes influenza A, influenza B, RSV, and an internal control, operating in conjunction with Molecular Designs’ Simplicity Dx Extraction products.

Built with a breakaway format, the panel enables laboratories to process only the required tests with minimal pipetting. This is intended to reduce waste and streamline inventory for facilities facing staffing limits or fluctuating seasonal demand, while also accommodating batch processing on busier days.

Molecular Designs chief scientific officer Greer Massey said: “Our goal was never just to add another respiratory test. We set out to design one around how clinical labs actually work, with quality and efficiency as priorities from the start. Every choice, from the assay format to the run controls, came from working alongside lab teams and listening to what they need day to day.”

SimplicityDx is designated for prescription use only within laboratories certified under clinical laboratory improvement amendments (CLIA) to conduct high-complexity testing.

Headquartered in Birmingham, Alabama, Molecular Designs was founded by physicians to make molecular testing simpler and more cost-effective.

The company manufactures instruments, reagents, components, and PCR-based assays in compliance with good manufacturing practice (GMP) and ISO 13485:2016 standards.

Its portfolio encompasses products labelled for research use only (RUO), which are not for diagnostic procedures, alongside SimplicityDx.